Preparing for the NASH epidemic: A call to action.

[1]  K. Cusi,et al.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.

[2]  S. Asch,et al.  Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality , 2020, JAMA network open.

[3]  F. Tacke,et al.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors , 2020, Nature Reviews Gastroenterology & Hepatology.

[4]  K. Cusi,et al.  Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. , 2020, Contemporary clinical trials.

[5]  A. Mithal,et al.  Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial) , 2020, Diabetologia.

[6]  V. Wong,et al.  Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes , 2020, Hepatology communications.

[7]  N. Byrne,et al.  The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial , 2020, Diabetes Care.

[8]  C. Mantzoros,et al.  The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease , 2020, Metabolism.

[9]  M. Stepanova,et al.  Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  V. Wong,et al.  Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Non-alcoholic Steatohepatitis-related, Child-Pugh A Cirrhosis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  T. Cotter,et al.  Nonalcoholic Fatty Liver Disease 2020: The State of the Disease , 2020 .

[12]  M. Clark,et al.  Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  P. Bossuyt,et al.  Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. , 2020, Journal of hepatology.

[14]  C. Thompson,et al.  Effect of Aspiration Therapy on Obesity-Related Comorbidities: Systematic Review and Meta-Analysis , 2020, Clinical endoscopy.

[15]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[16]  K. Cusi.  A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[17]  K. Cusi,et al.  Non-Alcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? , 2020, The American journal of medicine.

[18]  K. Cusi.  Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes , 2020, Diabetes Care.

[19]  S. Asch,et al.  Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease , 2020, Hepatology.

[20]  V. Wong,et al.  Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease , 2020, Journal of gastroenterology and hepatology.

[21]  M. Riddle,et al.  Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers , 2019, Clinical Diabetes.

[22]  F. Tacke,et al.  A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. , 2020, Journal of hepatology.

[23]  F. Violi,et al.  Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  R. DeFronzo,et al.  Insulin Resistance and Atherosclerosis: Implications for Insulin Sensitizing Agents. , 2019, Endocrine reviews.

[25]  C. Mantzoros,et al.  Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study. , 2019, Metabolism: clinical and experimental.

[26]  R. Haidry,et al.  Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results , 2019, JHEP reports.

[27]  K. Cusi,et al.  Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes , 2019, Diabetes Care.

[28]  O. Cummings,et al.  Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease , 2019, JAMA network open.

[29]  O. Cummings,et al.  Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. , 2019, The American journal of gastroenterology.

[30]  L. Longworth,et al.  Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[31]  D. Thorburn,et al.  Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.

[32]  K. Cusi,et al.  From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options , 2019, JHEP reports.

[33]  V. Wong,et al.  Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[34]  Z. Younossi,et al.  Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease , 2019, Hepatology communications.

[35]  F. Tacke,et al.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.

[36]  K. Cusi,et al.  Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2019, Diabetes Care.

[37]  T. Taddei,et al.  Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. , 2019, Gastroenterology.

[38]  M. Anvari,et al.  Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta‐analysis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[39]  K. Cusi,et al.  Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. , 2019, The lancet. Diabetes & endocrinology.

[40]  Z. Younossi,et al.  Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States , 2019, Hepatology.

[41]  O. Cummings,et al.  Vitamin E Improves Transplant‐Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis , 2020, Hepatology.

[42]  Cezary Szmigielski,et al.  Transfer learning with deep convolutional neural network for liver steatosis assessment in ultrasound images , 2018, International Journal of Computer Assisted Radiology and Surgery.

[43]  Joseph K. Lim,et al.  The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes , 2018, Clinical liver disease.

[44]  E. Speliotes,et al.  Treatment of Dyslipidemia in Common Liver Diseases , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[45]  Z. Younossi,et al.  Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD) , 2018, Medicine.

[46]  L. Serfaty.  Management of patients with non‐alcoholic steatohepatitis (NASH) in real life , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[47]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[48]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[49]  K. Cusi,et al.  Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[50]  L. Henry,et al.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018, Nature Reviews Gastroenterology & Hepatology.

[51]  P. Aschner.  F1000Prime recommendation of Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. , 2017 .

[52]  Siddharth Singh,et al.  Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta‐analysis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[53]  Jasjit S. Suri,et al.  Extreme Learning Machine Framework for Risk Stratification of Fatty Liver Disease Using Ultrasound Tissue Characterization , 2017, Journal of Medical Systems.

[54]  V. Wong,et al.  Laboratory parameter‐based machine learning model for excluding non‐alcoholic fatty liver disease (NAFLD) in the general population , 2017, Alimentary pharmacology & therapeutics.

[55]  K. Cusi,et al.  Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial , 2017, The Journal of clinical endocrinology and metabolism.

[56]  H. Makhlouf,et al.  Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease , 2017, Hepatology communications.

[57]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[58]  K. Cusi,et al.  Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease , 2017, Hepatology.

[59]  I. Raz,et al.  Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes , 2017, Expert review of clinical pharmacology.

[60]  F. Violi,et al.  Under-prescription of statins in patients with non-alcoholic fatty liver disease. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[61]  T. Kawaguchi,et al.  Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. , 2017, Journal of hepatology.

[62]  J. Gottdiener,et al.  The association of lean and fat mass with all-cause mortality in older adults: The Cardiovascular Health Study. , 2016, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[63]  K. Cusi,et al.  Pharmacological management of nonalcoholic fatty liver disease. , 2016, Metabolism: clinical and experimental.

[64]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[65]  S. Sookoian,et al.  How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals? , 2016, Gastroenterology.

[66]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[67]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[68]  H. El‐Serag,et al.  Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia , 2016, Digestive Diseases and Sciences.

[69]  J. Hardies,et al.  Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[70]  E. Bugianesi,et al.  Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander , 2015, Seminars in Liver Disease.

[71]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[72]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[73]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[74]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[75]  H. El‐Serag,et al.  Nonalcoholic Fatty Liver Disease is Underrecognized in the Primary Care Setting , 2015, The American Journal of Gastroenterology.

[76]  K. Cusi,et al.  The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease , 2015, Hepatology.

[77]  H. Makhlouf,et al.  Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) , 2013, Digestive Diseases and Sciences.

[78]  James E. Nelson,et al.  Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease , 2012, Hepatology.

[79]  Eliseo Guallar,et al.  Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis , 2011, Hepatology.

[80]  Sarah A. Moore,et al.  Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss , 2011, Gut.

[81]  O. Cummings,et al.  Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network , 2011, Hepatology International.

[82]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[83]  Julien Vergniol,et al.  Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease , 2010, Hepatology.

[84]  D. Reeds,et al.  Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. , 2009, Gastroenterology.

[85]  J. Barkin.  A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis , 2007 .

[86]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[87]  K. Lundbaek,et al.  European Association for the study of diabetes , 1969, Diabetologia.